Is Aducanumab a Miracle Drug?
Keywords:Aducanumab, Aduhelm, Amyloid-Beta, Tau, Brain, Biogen
A new drug called Aducanumab has been circulating the medical news for a while along with many questions. To answer these questions, it is imperative to understand Alzheimer’s disease. This research was done by reading other articles and observing scans to truly comprehend the premise of the problems. It was found that Alzheimer’s is caused by the clumping of amyloid-beta proteins and tau proteins which kill the neuron. The drug, that is in question, is an immunotherapeutic drug that is prescribed for moderately severe cases of Alzheimer’s. The trials were done on a variety of people and different stages of Alzheimer’s. They tested different doses and compared the values to a placebo. This was all monitored by MRI scans to any decrease in amyloid plaque and to monitor the possible systems. Through the observation of different trials and testing, it is still not clear if the drug truly works and is worth taking. In some studies, Aducaumab has been seen to work positively and had a substantial difference in the amount of plaque reduced compared to the placebo values. However, some of the later studies say otherwise because there is not much plaque reduction and the symptom called ARIA-E. This drug is different in its approach from other drugs in the sense that it actually targets the amyloid plagues. According to a neuro physician, many doctors are willing to give this medication a try and closely monitor a patient if the patient falls under the right category for treatment. Overall, questions about this drug are still yet to be answered.
References or Bibliography
Aducanumab - an overview | ScienceDirect Topics. (n.d.).
Aduhelm - FDA prescribing information, side effects and uses. (n.d.).
Alzheimer's Association. (2020). Facts and Figures.
Ferrero, J., Williams, L., Stella, H., Leitermann, K., Mikulskis, A., O’Gorman, J., & Sevigny, J. (2016). First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer’s disease. Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2(3), 169–176.
Kastanenka, K. V., Bussiere, T., Shakerdge, N., Qian, F., Weinreb, P. H., Rhodes, K., & Bacskai, B. J. (2016). Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice. The Journal of Neuroscience, 36(50), 12549–12558.
National Institute on Aging. (2018, April 1). How Is Alzheimer’s Disease Treated? Retrieved from National Institute on Aging website:
Richards, S. S., & Hendrie, H. C. (1999). Diagnosis, Management, and Treatment of Alzheimer Disease. Archives of Internal Medicine, 159(8), 789.
Salloway, Stephen, et al. “Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients with Early Alzheimer Disease.” JAMA Neurology, 22 Nov. 2021, 10.1001/jamaneurol.2021.4161.
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., … Engber, T. (2016). The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature, 537(7618), 50–56.
Tolar, M., Abushakra, S., Hey, J. A., Porsteinsson, A., & Sabbagh, M. (2020). Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval. Alzheimer’s Research & Therapy, 12(1).
Weller, J., & Budson, A. (2018). Current understanding of Alzheimer’s disease diagnosis and treatment. F1000Research, 7(1), 1161. https://doi.org/10.12688/f1000research.14506.1
What Is Aduhelm and How Does It Fight Alzheimer’s? (2021, June 10).
How to Cite
Copyright (c) 2022 Sanjana Ananthula; Rajagopal Appavu, Josthana Kethar
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.